AUPH Aurinia Pharmaceuticals
- 8.010
- +0.270+3.49%
- 8.040
- +0.030+0.37%
Aurinia Pharmaceuticals News
Aurinia Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director TANG KEVIN
Aurinia Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Smith Karen L.
Aurinia Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Leversage Jill
Aurinia Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Johnson Craig A
Aurinia Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bailey Jeffrey Allen
Aurinia Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Jayne David R.W.
Aurinia Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(5.73%),Steven Boyd(5.73%)
Aurinia Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bailey Jeffrey Allen
Aurinia Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Smith Karen L.
Aurinia Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Officer Keenan Greg
Aurinia Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Johnson Craig A
Aurinia Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Aurinia Pharmaceuticals | 8-K: Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS ® Growth and AUR200 Development
Aurinia Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director TANG KEVIN
Aurinia Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities- MacKay-Dunn R. Hector
Aurinia Pharmaceuticals | SC 13D: Statement of acquisition of beneficial ownership by individuals-TANG CAPITAL MANAGEMENT, LLC(5.1%),KEVIN TANG(5.1%), etc.
Aurinia Pharmaceuticals | 8-K: Current report
Aurinia Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Habig Scott Michael
Aurinia Pharmaceuticals | 8-K: AURINIA PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTHS 2024 FINANCIAL AND OPERATIONAL RESULTS
Aurinia Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
No Data